BioMarin Pharma (BMRN) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BioMarin (BMRN) Reiterates Profitability in 2017 - Piper Jaffray
February 26, 2016 9:46 AM ESTPiper Jaffray analyst, Joshua Schimmer, sees numerous catalysts for BioMarin (NASDAQ: BMRN) as the company marches toward profitability. No change to Overweight rating but the PT is revised down to $107.
BMRN has spent years with aggressive opex and burning cash on a promising pipeline. But much of that pipeline is now close to graduating towards commercial products and it's time for the company to move towards generating cash flows for investors while also finding new programs to replace... More
